drugset / Trial / NCT01908387
Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms
NaSingle-groupOpen-labelTreatment
Summary
To identify the maximum tolerated dose (MTD) of oral azacitidine on different treatment schedules in Japanese subjects with hematological neoplasms
Timeline
- Start
- 2013-07
- Primary completion
- 2015-07
- Completion
- 2015-07
Outcome
Outcome not reported
Stopped (Enrollment): “Due to Slow Accrual study was terminated.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 100 mg | Oral |
| Subject | Azacitidine | Other / unclassified | 300 mg | Oral |